表纸
市场调查报告书

Biomedtracker /目标设备追踪:2020年第3季预测

Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

出版商 Datamonitor Healthcare 商品编码 955915
出版日期 内容资讯 英文 52 Pages
商品交期: 最快1-2个工作天内
价格
Biomedtracker /目标设备追踪:2020年第3季预测 Biomedtracker / Meddevicetracker Q3 2020 Outlook Report
出版日期: 2020年07月01日内容资讯: 英文 52 Pages
简介

本报告提供2020年的第3季预测的药物,设备,诊断,催化剂的交易相关调查,各药物的特定phase,药物类别,根据疾病群组的phase/PDUFA审查的成功概率与整体核准取得可能性(LOA)等。

成为对象的适应症:

  • 痤疮
  • 急性骨髓性白血病(AML)
  • Angelman症候群
  • 躁鬱症
  • 心脏瓣膜手术
  • COVID-19
  • 弥漫性大型B细胞淋巴癌(DLBCL)-NHL
  • 移植物抗宿主病(GVHD)-治疗
  • A型血友病
  • 高草酸尿症
  • 缺血性中风
  • 严重抑鬱症(MDD)
  • 套细胞淋巴瘤-NHL
  • 多发性骨髓瘤(MM)
  • 多发性硬化症(MS)
  • 骨髓增生异常症候群(MDS)
  • 骨关节炎和骨关节炎的疼痛
  • 其他的眼科症状(眼科)
  • 肾脏疾病/肾功能衰竭
  • 类风湿性关节炎(RA)
  • 硬皮症
  • 发作障碍(癫痫)
  • 脊髓性肌萎缩症

目录

  • 目录
  • 概要
  • 关于作者
  • 免责声明
  • 来自2020年第2季预测报告的结果
  • 药品
  • 痤疮:Winlevi/Breezula(SKIN)
  • 急性骨髓性白血病(AML):Oral Azacitidine(BMY)
  • Angelman症候群:OV101 (OVID)
  • 躁鬱症:Caplyta(ITCI)
  • COVID-19:Actemra(RHHBY)
  • COVID-19:Kevzara(SNY)
  • 弥漫性大型B细胞淋巴癌(DLBCL):MOR208-NHL(MOR)
  • 移植物抗宿主病(GVHD):Ryoncil - 治疗(MESO)
  • A型血友病:Roctavian (BMRN)
  • 高草酸尿症:Lumasiran (ALNY)
  • 大忧鬱症性障碍(MDD)的Nuplazid (ACAD)
  • 大忧鬱症性障碍(MDD)的Nuplazid (ACAD)
  • 套细胞淋巴瘤的KTE-X19-NHL(GILD)
  • 多发性骨髓瘤(MM)的Belantamab Mafodotin(GSK)
  • 多发性硬化症(MS)的Arzerra(自体免疫)(NVS)
  • 骨髓增生异常症候群(MDS)的ASTX727(大冢)等
目录
Product Code: #BMT

Overview

In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa's drug development benchmarking product utilizing Biomedtracker's LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. The results of the drug catalysts highlighted in our Biomedtracker / Meddevicetracker Q2 2020 Outlook Report can be found on Page 6. At the end of this report, we have included a list of Large Impact catalysts through Q3 2020.

Indications Covered:

  • Acne
  • Acute Myelogenous Leukemia (AML)
  • Angelman Syndrome
  • Bipolar Disorder
  • Cardiac Valve Surgery

COVID-19

  • Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
  • Graft vs. Host Disease (GVHD) - Treatment
  • Hemophilia A
  • Hyperoxaluria
  • Ischemic Stroke
  • Major Depressive Disorder (MDD)
  • Mantle Cell Lymphoma - NHL
  • Multiple Myeloma (MM)
  • Multiple Sclerosis (MS)
  • Myelodysplastic Syndrome (MDS)
  • Osteoarthritis and Osteoarthritis Pain
  • Other Ophthalmological Indications (Ophthalmology)
  • Renal Disease / Renal Failure
  • Rheumatoid Arthritis (RA)
  • Scleroderma
  • Seizure Disorders (Epilepsy)
  • Spinal Muscular Atrophy

TABLE OF CONTENTS

  • Contents
  • Summary
  • About the Author
  • Disclaimer
  • Outcomes of Biomedtracker's Large Impact Drug Catalysts from the Q2 2020 Outlook Report
  • Drugs
  • Winlevi / Breezula for Acne (SKIN)
  • Oral Azacitidine for Acute Myelogenous Leukemia (AML) (BMY)
  • OV101 for Angelman Syndrome (OVID)
  • Caplyta for Bipolar Disorder (ITCI)
  • Actemra for COVID-19 (RHHBY)
  • Kevzara for COVID-19 (SNY)
  • MOR208 for Diffuse Large B-Cell Lymphoma (DLBCL) - NHL (MOR)
  • Ryoncil for Graft vs. Host Disease (GVHD) - Treatment (MESO)
  • Roctavian for Hemophilia A (BMRN)
  • Lumasiran for Hyperoxaluria (ALNY)
  • Nuplazid for Major Depressive Disorder (MDD) (ACAD)
  • Nuplazid for Major Depressive Disorder (MDD) (ACAD)
  • KTE-X19 for Mantle Cell Lymphoma - NHL (GILD)
  • Belantamab Mafodotin for Multiple Myeloma (MM) (GSK)
  • Arzerra (Autoimmune) for Multiple Sclerosis (MS) (NVS)
  • ASTX727 for Myelodysplastic Syndrome (MDS) (Otsuka)
  • CNTX-4975 for Osteoarthritis and Osteoarthritis Pain (CNTX)
  • RVL-1201 for Other Ophthalmological Indications (Ophthalmology) (OSMT)
  • Veverimer for Renal Disease / Renal Failure (TCDA)
  • Filgotinib for Rheumatoid Arthritis (RA) (GILD)
  • Lenabasum for Scleroderma (CRBP)
  • Ganaxolone for Seizure Disorders (Epilepsy) (MRNS)
  • Risdiplam for Spinal Muscular Atrophy (RHHBY)
  • Devices
  • Portico TAVI System for Cardiac Valve Surgery (ABT)
  • Ischemic Stroke System (ISS) for Ischemic Stroke (BrainsGate)
  • Deals
  • Alexion to Acquire Portola
  • Neurotrope and Metuchen to Merge
  • Tetraphase to be Acquired by La Jolla Pharmaceuticals
  • Q3 2020 Large Impact Catalysts